Pharma Dialogue – Competence Team III holds meeting
The continuation of the Pharma Dialogue has involved competence teams working on various thematic areas. Competence Team III is focusing on technologies and trends. In the Team’s May meeting, the Federal Institute for Drugs and Medical Devices (BfArM) gave a report on translational medicine. BfArM emphasised the importance of cooperation with academia in order to enable new projects to be set up early on in such a way that prevents regulatory requirements in later development phases from posing an obstacle to translation. In addition, a representative from Celgene presented new gene therapy approaches that use CAR T-cells while also pointing out obstacles that are hindering research and development.